Abstract: This disclosure describes, in part, a mobile apparatus for identifying items. For instance, the mobile apparatus may include a frame, a basket that attaches to the frame, a tray that attaches to the frame, and a user-facing module that attaches to the frame. Weight sensors may be located beneath the basket and the tray in order to determine the weights of items added to the mobile apparatus. The user-facing module may include imaging devices, such as cameras, that the mobile apparatus uses to perform one or more functions. For example, the mobile apparatus may use the imaging devices to identify items placed within the basket, determine locations of the mobile apparatus within a facility, and/or the like. By including these components, the mobile apparatus is able to generate data that represents the items added to the mobile apparatus, the weights of the items, and the costs of the items.

Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: A method for detection and use of device identifiers to enhance the security of data transfers between electronic devices. A first electronic device can transmit access data to a second electronic device. The access data can be associated with a first access code that can be generated based at least in part on data representing a device identifier of the first electronic device. A device identifier can uniquely identify the first electronic device from a plurality of electronic devices. Transferring the access data can involve transforming the first access code into a second access code that can include data representing a device identifier associated with the second electronic device. Transforming the first access code into the second access code can facilitate access to a resource associated with the access data for a second user, but not for a first user.

Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: A method for detection and use of device identifiers to enhance the security of data transfers between electronic devices. A first electronic device can transmit access data to a second electronic device. The access data can be associated with a first access code that can be generated based at least in part on data representing a device identifier of the first electronic device. A device identifier can uniquely identify the first electronic device from a plurality of electronic devices. Transferring the access data can involve transforming the first access code into a second access code that can include data representing a device identifier associated with the second electronic device. Transforming the first access code into the second access code can facilitate access to a resource associated with the access data for a second user, but not for a first user.

Abstract: A method for detection and use of device identifiers to enhance the security of data transfers between electronic devices. A first electronic device can transmit access data to a second electronic device. The access data can be associated with a first access code that can be generated based at least in part on data representing a device identifier of the first electronic device. A device identifier can uniquely identify the first electronic device from a plurality of electronic devices. Transferring the access data can involve transforming the first access code into a second access code that can include data representing a device identifier associated with the second electronic device. Transforming the first access code into the second access code can facilitate access to a resource associated with the access data for a second user, but not for a first user.

Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

Abstract: A computer-based ticket system enables users to electronically transfer tickets to other users, and to obtain tickets from other users. A first software module executing in a server is configured to cancel a first ticket for a first seat at first event associated with a first user, and issue a second ticket for the first seat to a second user at least partly in response to an instruction from the first user received from a first user terminal and an instruction from the second user received from a second user terminal.

Abstract: The present disclosure provides anti-albumin constructs each comprising an antialbumin single-domain antibody (sdAb) moiety. The anti-albumin constructs can further comprise a therapeutic agent, such as an antigen binding moiety or a cytokine. The present disclosure also provides methods of making and using the anti-albumin constructs.

Abstract: Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.

Abstract: Provided herein are an interleukin-2 polypeptide and a fusion protein thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: The present application relates to anti-mesothelin constructs (such as antimesothelin antibodies, cytokine fusion proteins that comprise the anti-mesothelin constructs), methods of preparing the anti-mesothelin constructs and methods of using the constructs (e.g., methods of treating a disease or condition). The present application also relates to a combination therapy for treating cancer that comprises administering anti-mesothelin agent and a cytokine (such as IL-21 or IL-15). Combination therapy may further comprises administration of an anti-Her2 agent.

Abstract: A method for detection and use of device identifiers to enhance the security of data transfers between electronic devices. A first electronic device can transmit access data to a second electronic device. The access data can be associated with a first access code that can be generated based at least in part on data representing a device identifier of the first electronic device. A device identifier can uniquely identify the first electronic device from a plurality of electronic devices. Transferring the access data can involve transforming the first access code into a second access code that can include data representing a device identifier associated with the second electronic device. Transforming the first access code into the second access code can facilitate access to a resource associated with the access data for a second user, but not for a first user.

Abstract: The present application provides fusion proteins that comprise a cytokine fused to an albumin binding moiety. The fusion proteins may further comprise an antigen binding moiety such as a therapeutic antibody. The present application also provides methods of making and using the fusion proteins. The present application also provides methods of treatment comprises administering a fusion protein comprising a cytokine fused to a half-life extending domain and a second agent.

Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

Abstract: A method for detection and use of device identifiers to enhance the security of data transfers between electronic devices. A first electronic device can transmit access data to a second electronic device. The access data can be associated with a first access code that can be generated based at least in part on data representing a device identifier of the first electronic device. A device identifier can uniquely identify the first electronic device from a plurality of electronic devices. Transferring the access data can involve transforming the first access code into a second access code that can include data representing a device identifier associated with the second electronic device. Transforming the first access code into the second access code can facilitate access to a resource associated with the access data for a second user, but not for a first user.

Abstract: A method for detection and use of device identifiers to enhance the security of data transfers between electronic devices. A first electronic device can transmit access data to a second electronic device. The access data can be associated with a first access code that can be generated based at least in part on data representing a device identifier of the first electronic device. A device identifier can uniquely identify the first electronic device from a plurality of electronic devices. Transferring the access data can involve transforming the first access code into a second access code that can include data representing a device identifier associated with the second electronic device. Transforming the first access code into the second access code can facilitate access to a resource associated with the access data for a second user, but not for a first user.

Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.